Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
RESEARCH TOOLSreports
Holding NRXP?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.32Last Year’s EPS
-0.5Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 16, 2021
|% Change Since: 245.69%
|Next Earnings Date:Aug 17, 2021
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in reducing operating losses, advancing drug development, and strategic acquisitions. However, challenges remain in cash reserves, acquisition strategies, and revenue recognition policies. The company's outlook is optimistic with planned new drug applications and potential profitability by 2025.Company Guidance
During the NRx Pharmaceuticals Third Quarter 2024 Earnings Call, the company provided several key metrics and guidance for the upcoming periods. NRx Pharmaceuticals achieved a 74% reduction in net operating losses compared to the third quarter of 2023, forecasting profitability in 2025 with anticipated revenue and EBITDA contributions from their subsidiary, Hope Therapeutics, alongside expected drug sales. The company secured $10.8 million in funding from an institutional investor, helping to retire expensive debt. The revenue target for Hope Therapeutics is set at $25 million by the end of 2024 and over $100 million by the end of 2025. Additionally, NRx plans to file NDAs for NRX-100 and NRX-101, with anticipated PDUFA dates in 2025.Significant Reduction in Operating Loss
NRx Pharmaceuticals achieved a 74% reduction in net operating losses compared to the third quarter of 2023, forecasting profitability in 2025.
Progress in Drug Development
NRx advanced its life-saving products, NRX-100 and NRX-101, for new drug application filings in 2024, with potential FDA approvals expected in 2025.
Successful Acquisition Strategies
Hope Therapeutics signed nonbinding letters of intent to acquire two revenue-generating interventional psychiatry groups, with nondilutive acquisition financing close to finalization.
New CFO Appointment
Michael Abrams, with extensive financial and industry experience, appointed as the new Chief Financial Officer.
Reduction in R&D and G&A Expenses
Research and development expenses decreased by 52% year-over-year, while general and administrative expenses decreased by 11%.
Funding and Debt Management
Closed second tranche of funding, bringing total to $10.8 million, retired prior expensive debt, and settled litigation with Streeterville Capital.
---
NRXP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NRXP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $1.16 | $1.19 | +2.59% |
| Aug 13, 2024 | $1.90 | $1.86 | -2.11% |
| May 14, 2024 | $3.18 | $3.23 | +1.57% |
| Apr 01, 2024 | $4.72 | $5.25 | +11.23% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does NRX Pharmaceuticals (NRXP) report earnings?
NRX Pharmaceuticals (NRXP) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is NRX Pharmaceuticals (NRXP) earnings time?
NRX Pharmaceuticals (NRXP) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NRXP EPS forecast?
NRXP EPS forecast for the fiscal quarter 2024 (Q4) is -0.32.
---